| Overview |
| bs-5916R-Cy5.5 |
| Annexin A9 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Annexin A9 |
| 261-345/345 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8416 |
| Cytoplasm, Secreted, Extracellular matrix |
| annexin 31; annexin A9; annexin XXXI; ANX31; ANXA9; ANXA 9; ANXA-9; pemphaxin; ANXA9_HUMAN . |
| ANXA9 may act as a low affinity receptor for acetylcholine and is expressed in the stratified squamous skin epithelium, but not in epithelia of other types (at protein level). ANXA9 is one of the target molecules recognized by auto in patients with pemphigus vulgaris, a rare, autoimmune skin disease in which epidermal blisters occur as the result of the loss of cell-cell adhesion. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz